深圳商报记者 苑伟斌 倍轻松实际控制人马学军再遭立案调查。2月6日公告显示，马学军不足一个半月两度遭证监会立案，这 意味着马学军或涉多项罪名。 近期，深陷多重困境的倍轻松披露了2025年度业绩预告，公司预计实现归母净利润亏损约8400万元至 1.05亿元。从历史业绩来看，2022年倍轻松在上市次年就首度出现亏损，此后的4年中有3年公司净利润 都为负值。 实控人减持、监管立案、专利诉讼等，这家曾经的"健康智能硬件第一股"风波不断，究竟因何经营至 此？未来修复之路又在何方？ 销售费用占比接近六成 财报显示，2025年前三季度，倍轻松实现营业收入约5.52亿元，同比减少34.07%，同期归母净利润亏损 6562.8万元，大幅缩水600.98%。根据公司披露的预计数据，倍轻松在2025年第四季度归母净利润亏损 大约1827.2万元至3937.2万元，而2024年第四季度公司归母净利润亏损约284.66万元，亏损幅度明显扩 大。 令人费解的是，倍轻松毛利率长期维持在60%左右的高位，2025年前三季度毛利率高达62.1%，却始终 难以实现稳定盈利。这一背后是重营销、轻研发发展模式的长期积弊。数据显示，2022年-202 ...

Core Viewpoint - The company reported a revenue decline of 16.12% in 2025, with a net profit loss of 55.84 million yuan, although it reduced its loss by 24.94% compared to the previous year [1] Financial Performance - In 2025, the company achieved a revenue of 433 million yuan, down from the previous year [1] - The net profit attributable to shareholders was -55.84 million yuan, indicating a reduction in losses compared to the previous year [1] - The company has experienced consecutive losses for four years, with net profits of -48.91 million yuan in 2022, -12.20 million yuan in 2023, -74.40 million yuan in 2024, and -55.84 million yuan in 2025 [2] Legal Issues - The former actual controller of the company was sentenced for damaging the company's interests, involving illegal financial activities that misappropriated company funds for personal use [3][4] - The court sentenced the former chairman to three years in prison and imposed a fine of 5 million yuan, while the former financial director received a sentence of one year and six months with a fine of 200,000 yuan [4] - The company received 62 million yuan in execution funds from the court as a result of the legal proceedings [5] Market Performance - As of the close on February 12, the company's stock price fell by 1.92%, trading at 9.18 yuan per share, with a total market capitalization of 1.138 billion yuan [6]

Core Viewpoint - The Shanghai Stock Exchange issued a regulatory warning to Shuangliang Energy due to misleading information regarding overseas orders related to commercial aerospace, which could mislead investors [3]. Group 1: Company Orders and Financial Impact - Shuangliang Energy announced three overseas orders for a total of 12 high-efficiency heat exchangers, intended for use in the fuel production system at SpaceX's Starship launch base, highlighting the trust in its products [1]. - The total value of these orders is approximately RMB 13.92 million, accounting for about 0.11% of the company's audited revenue for 2024, indicating no significant impact on the company's financial performance [2]. - The company clarified that it is not a direct partner with SpaceX and is merely a non-exclusive indirect supplier, with future order acquisition being subject to uncertainties in the commercial aerospace sector [2]. Group 2: Regulatory Response and Company Performance - The Shanghai Stock Exchange criticized the company for not providing sufficient details about the orders, including supply methods and the limited impact on overall operations, which could mislead investors [3]. - Following regulatory pressure, the company disclosed its expected net loss for 2025 to be between RMB 780 million and RMB 1.06 billion, marking the second consecutive year of significant losses, although the loss margin has narrowed compared to the previous year [4].

2月12日晚间，北京银行（601169）公告称，因到龄离任，霍学文先生申请辞去北京银行董事长、董事 会战略与社会责任（ESG）委员会主任委员、董事会消费者权益保护委员会主任委员职务。 值得注意的是，北京银行近期屡遭监管点名。 2025年12月31日，国家金融监督管理总局青岛监管局披露的公告显示，北京银行青岛分行因对公贷款管 理不审慎、违规办理票据业务被罚款80万元，4名相关责任人被警告。同年11月28日，中国人民银行公 布的行政处罚决定书显示，北京银行被警告、没收违法所得1886.3元，并罚款2526.85万元，涉及的违法 违规行为包括：违反账户管理规定；违反收单业务管理规定；违反代收业务管理规定；违反反假货币业 务管理规定；占压财政存款或者资金；违反信用信息采集、提供、查询及相关管理规定；未按规定履行 客户身份识别义务；未按规定报送大额交易报告或可疑交易报告；与身份不明的客户进行交易。 此外，2025年9月30日，国家金融监督管理总局北京监管局发布的行政处罚信息公开表显示，北京银行 因七项违法违规行为合计被罚530万元，责任人徐凯、王瑾被警告并处罚款5万元。 与此同时，北京银行透露，董事会2026年第二次会 ...

常态亏损的长生人寿2025年继续亏损——在行业整体向好的背景下，公司保险业务收入同比下滑，在57家非上市人身险公司中降幅居前；年度净亏损超过 5亿元。长生人寿官网信息还显示，公司2025年第四季度综合偿付能力充足率为79.7%，2025年第二季度风险综合评级为B类；偿付能力充足率未达到监管 要求。 | 长生人寿保险有限公司 | 首页 | 走进我们 | 产品中心 | 新闻公告 | 客户服务 | | --- | --- | --- | --- | --- | --- | | 公开信息披露 | 偿付能力季度报告摘要 | | 〇 您的位置： 首页-公开信息披露专栏-专项信息-偿休 | | | | | | | 最近季度偿付能力信息 | | | | | | | | | 更新时间: | | | | 里V: 力兀 | | --- | --- | --- | | 指标名称 | 本季度数 | 本年累计数 | | 保险业务收入 | 39,899 | 192,605 | | 浄利润 | -12,611 | -51,220 | | 总资产 | 1,466,686 | 1,466,686 | | 净资产 | -22,646 | -22, ...

2月12日盘后，绿地控股（600606）发布公告，公司及控股子公司在2026年1月23日至2026年2月10日新增诉讼1566件，累计金额60.4亿元。 具体来看，公司作为被告的诉讼事项共有1455件，累计金额52.89亿元。其中建设工程施工/采购诉讼纠纷663件，金额26.81亿元；房地产买卖/租赁诉讼纠 纷519件，金额3.74亿元；其他诉讼纠纷273件，金额22.34亿元。 作为原告的诉讼事项共有111件，累计金额7.51亿元。其中，建设工程施工/采购诉讼纠纷44件，金额4.61亿元；房地产买卖/租赁诉讼纠纷36件，金额1.42 亿元；其他诉讼纠纷31件，金额1.48亿元。 19天新增1566件官司，且多为被告方。若这些未决案件判决结果对公司不利，绿地控股将承担大额赔偿或支付义务，直接冲击当期利润和现金流。公司指 出，当前房地产及基建行业仍处于调整周期，面临较大压力，因此高度重视诉讼化解工作，采取了包括组建工作专班、实施领导包案等措施，公司表示将 持续加大工作力度，妥善处理相关诉讼，以减小对经营活动的影响，并保护投资者的合法权益。 编辑信嘉毅责编朱峰校审梁荣高 2025年11月14日至12月2日新增诉讼 ...

Group 1 - The Hunan Securities Regulatory Bureau issued a warning letter to Changjiang Securities' Changsha Wanjin Avenue Securities Business Department due to various compliance issues [1][2] - The identified problems include inadequate management of brokers, irregular performance assessment incentives, imprudent product cancellation management, and insufficient management of blank vouchers and seals [2] - Changjiang Securities has a history of compliance violations, including issues with unqualified personnel, untimely deregistration of staff, and incomplete records in investment advisory services [3] Group 2 - Changjiang Securities, established in 1991 and listed on the Shenzhen Stock Exchange in 2007, offers a wide range of services including securities brokerage, investment banking, asset management, and private equity [4] - The company expects to achieve a net profit of 3.695 billion yuan in 2025, representing a year-on-year growth of 101.37% [4] - As of February 12, the stock price of Changjiang Securities closed at 7.96 yuan per share, with a total market capitalization of 44.02 billion yuan [5]

2月11日，港交所官网显示，博纳西亚（杭州）医药科技股份有限公司（以下简称"博纳西亚"）正式向港交所主板递 交上市申请，兴证国际、工银国际为其联席保荐人。 博纳西亚的服务范围涵盖整个临床开发过程，包括新药临床试验申请（IND）、I-IV期临床研究、新药上市申请 （NDA）注册申报以及FSP服务及其他服务。 招股书显示，博纳西亚在2026年1月22日刚刚改制为股份有限公司，并更名。截至最后实际可行日期，公司创始 人、董事会主席兼总经理赵敏先生直接持股61.01%，并通过博达创新（持股12.99%）及博华创新（持股4.33%）间 接持股。赵敏合计控制公司已发行股本总额约78.33%，处于绝对控股地位，为公司实控人。 在招股书中，博纳西亚亮出了一份毛利率、净利率、人均创收均碾压行业平均水平的成绩单。 | 【繼續】的【贈獲】數目 : [編纂]股H股(視乎[編纂] | | | --- | --- | | 行使與否而定) | | | [編纂]數目 | .. [編纂]股H股(可予[編纂]) | | [編纂]數目 | : [編纂]股H股(可予[編纂]及 | | 視乎[編纂]行使與否而定) | | | 最高[編纂] : 每股H ...

Core Viewpoint - Qushui Technology (301336) has faced two incidents of miscommunication in February 2026, including a correction regarding a share transfer announcement due to a clerical error in unit representation [1] Group 1: Share Transfer Announcement - The share transfer involves 2,000,000 shares of common stock (A-shares) from the transferor, Shunwei Investment, to the transferee, Hangzhou Runxi [2][3] - The transfer represents 5.00% of the company's total share capital as of the signing date of the share transfer agreement, and 5.04% when excluding repurchased shares [2][3] - The transfer price is set at RMB 54.946 per share, totaling approximately RMB 109.892 million [2][3] - The payment for the share transfer will be made in cash, sourced from the transferee's own funds [2][3] Group 2: Company Background and Financial Performance - Qushui Technology specializes in the research, design, production (outsourced), and sales of high-quality, easy-to-install furniture and home textile products [6] - Over 60% of the company's sales come from Xiaomi's ecosystem, with 15% and 10% from JD.com and Alibaba platforms, respectively; online sales account for over 90% of total sales [6] - For the first three quarters of 2025, the company reported total revenue of RMB 213 million, a year-on-year increase of 10.60%, and a net profit attributable to shareholders of RMB 21.63 million, up 13.46% [6]

Core Viewpoint - The company Guangkang Biochemical announced a share reduction plan by specific shareholders, which may indicate a potential shift in investor sentiment and could impact the stock price in the near term [1][10]. Shareholder Reduction Plans - Specific shareholders, including Huatuo Zhiying No. 2, Huatuo Zhiyuan No. 3, and Ruihong Kaiyin No. 1, plan to reduce their holdings within three months from the announcement date through centralized bidding and block trading [1][4]. - Huatuo Zhiying No. 2 and Huatuo Zhiyuan No. 3 plan to collectively reduce up to 1.3198 million shares, accounting for 1.7835% of the total share capital, while Ruihong Kaiyin No. 1 plans to reduce up to 1.98 million shares, representing 2.6757% of the total share capital [4][6]. Historical Context of Share Reductions - The shareholders are preparing for a "clearance-style" reduction, with Ruihong Kaiyin No. 1 having previously announced a similar reduction plan in October 2025, which was not executed [7]. - Huatuo Zhiying No. 2 and Huatuo Zhiyuan No. 3 had also announced a reduction plan in September 2025, resulting in a decrease in Huatuo Zhiyuan No. 3's holding from 0.6022% to 0.5884% [7]. Company Background - Guangkang Biochemical is a national high-tech enterprise specializing in the research, production, and sales of pesticide active ingredients, intermediates, and formulations [8]. - The company received a warning letter from the Guangdong Securities Regulatory Bureau a month prior to the announcement of the share reduction [10]. Financial Management Issues - From July 2023 to August 2025, the company used raised funds for cash management, purchasing 179 financial products, of which 158 were non-principal guaranteed products. The company did not adequately disclose the risks associated with these investments in its reports [10]. Stock Performance - The timing of the reduction announcement coincides with a nearly 20% rebound in the company's stock price from February 6 to February 11. Following the announcement, the stock initially dipped but later rebounded, closing up over 5% [10].